Tissue Plasminogen Activator Release in Chronic Venous Hypertension due to Heart Failure

Summary

In order to study the effects of chronic venous hypertension due to heart failure on blood fibrinolytic activity, tissue plasminogen activator (t-PA) antigen, plasminogen activator inhibitor 1 (PAI-1) antigen, t-PA activity and PAI activity were measured before and after venous occlusion of the arm for 20 min in 15 patients with right-sided heart failure, 15 patients with left-sided heart failure, and 30 control healthy subjects. Central venous pressure, measured by observing the jugular veins, was above 15 cm of the blood column in all patients with right-sided heart failure, and normal (below 8 cm) in all patients with left-sided heart failure and control subjects. There was no difference in the basal concentrations of t-PA (11.0, 10.2 and 10.8 ng/ml; all values medians) and PAI-1 antigens and their activities between right and left-sided heart failure and the control subjects. After the occlusion, t-PA antigen increased significantly less in right-sided heart failure (28.6 ng/ml) than in left-sided heart failure and the control subjects (54.5 and 45.9 ng/ml, respectively). It was concluded that the poor increase in fibrinolytic activity that had already been reported in patients with heart failure, was due to low t-PA release during occlusion and not to a high basal PAI level. It was limited to the patients with right-sided heart failure and was probably the consequence of chronic systemic venous hypertension.

• References

• 1 Robertson BR, Pandolfi M, Nilsson IM. Response of local fibrinolytic activity to venous occlusions of arms and legs in healthy volunteers. Acta Chir Scand 1972; 138: 437-440
• 2 Keber D. The increase of leg fibrinolytic potential after reduction of hydrostatic stimulus. Thromb Haemostas 1983; 50: 731-734
• 3 Keber D. Mechanism of tissue plasminogen activator release during venous occlusion. Fibrinolysis 1988; 2 suppl. 2 096-103
• 4 Keber D, Stegnar M. Exhaustion of arm fibrinolytic potential after repeated venous occlusions and local exercise. Thromb Res 1982; 28: 693-704
• 5 Sawyer WD, Fletcher AP, Alkjaersig N, Sherry S. Studies on the thrombolytic activity of human plasma. J Clin Invest 1960; 39: 426-434
• 6 Rawles JM, Ogston D, Douglas AS. Studies on the blood fibrinolytic system in congestive heart failure. Clin Sci Mol Med 1973; 45: 65-76
• 7 Keber D, Keber I. Decrease of arm fibrinolytic potential in right-sided heart failure as opposed to normal value in left-sided heart failure. Haemostasis 1984; 14: 114 (abstract)
• 8 Ranby M, Bergsdorf N, Nilsson T, Mellbring G, Winblad B, Bucht G. Age dependence of tissue plasminogen activator concentration in plasma, as studied by an improved enzyme-linked immunosorbent assay. Clin Chem 1986; 32: 2160-2165
• 9 Verheijen JH, Chang GTG, Kluft C. Evidence for the occurrence of a fast-acting inhibitor for tissue-type plasminogen activator in human plasma. Thromb Haemostas 1984; 51: 392-395
• 10 Verheijen JH, Mullaart E, Chang GTG, Kluft C, Wijngaards G. A simple and sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurements in plasma. Thromb Haemostas 1982; 48: 266-269
• 11 Keber D, Stegnar M, Kluft C. Different tissue plasminogen activator release in the arm and leg during venous occlusion is equalized after DDAVP infusion. Thromb Haemostas 1990; 63: 72-75
• 12 Declerck PJ, Alessi MC, Verstreken M, Kruithof EKO, Juhan-Vague I, Collen D. Measurement of plasminogen activator inhibitor 1 in biologic fluids with murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 1988; 71: 220-225
• 13 Keber D. On the use of different correction factors for hemoconcentration. Thromb Haemostas 1983; 49: 245
• 14 Keber D, Blinc A, Fettich J. Increase of tissue plasminogen activator in limbs during venous occlusion: a simple haemodynamic model. Thromb Haemostas 1990; 64: 433-437
• 15 Braunwald E. Clinical manifestations of heart failure. In: Heart Disease. A Textbook of Cardiovascular Medicine.. Braunwald E. (ed) WB Saunders Co, Philadelphia, PA: 1988. pp 471-484
• 16 Kruithof EKO, Nicoloso G, Bachmann F. Plasminogen activator inhibitor 1: Development of a radioimmunoassay and observations on its plasma concentration during venous occlusion and after platelet aggregation. Blood 1987; 70: 1645-1653
• 17 Booth NA, Simpson AJ, Croll A, Bennet B, MacGregor IR. Plasminogen activator inhibitor (PAI 1) in plasma and platelets. Br J Haematol 1988; 70: 327-333
• 18 Nilsson IM, Ljungner H, Tengborn L. Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor. Br Med J 1985; 290: 1453-1456
• 19 Wiman B, Ljungberg B, Chmielewska J, Urden G, Blombäck M, Johnsson H. The role of the fibrinolytic system in deep vein thrombosis. J Lab Clin Med 1985; 105: 265-270
• 20 Juhan-Vague I, Valadier J, Alessi MC. et al Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis. Thromb Haemostas 1987; 57: 67-72
• 21 Korniger C, Lechner K, Niesnner H, Gossinger H, Kundi M. Impaired fibrinolytic capacity predisposes for recurrence of venous thrombosis. Thromb Haemostas 1984; 52: 127-130
• 22 Prescott SM, Tikoff G. Deep venous thrombosis of the upper extremity: a reappraisal. Circulation 1979; 59: 350-355